According to FutureWise analysis the market for Transplant Diagnostics in 2023 is US$ 4.74 billion, and is expected to reach US$ 8.52 billion by 2031 at a CAGR of 7.60%.
Rising number of stem-cell-based, soft tissues, and solid transplantation, increasing geriatric population, rising occurrence of persistent diseases, augmentation in laboratory automation of diagnostic operations that are assisted by robots and advancements in technology advancement in human leukocyte antigen typing are some of the crucial factors driving the growth of the global transplant diagnostics market. Additionally, an increase in public and private investments to develop novel human leukocyte antigen (HLA) products for testing, soaring number of HLA applications in diagnostics, improvement in healthcare infrastructure, especially in developing nations, consistent reduction average gene sequencing costs and rising bases of installation of NGS and PCR instruments are steering the global transplant diagnostic market growth. Although, factors like high NGS and PCR instrument costs, finite medical rendering for transplantation operations and a massive difference between annual transplantation and organ donation are the important factors responsible for impeding market growth.
Increasing penetration of the market in emerging economies in order to develop products of transplant diagnostics and rising priority shift from using serological assay method to HLA profiling based on genomes would open further opportunities for the growth of the transplant diagnostic market. New product developments and product announcements are amongst the primary global market trends.
North America subjugates the global market owing to consistent gene sequencing average cost reduction, public and funding for HLA development and increasing number of solid organ and stem cell-based transplantation in the region. The Asia Pacific region is predicted to showcase a high growth rate in the next decade in the global market with India and China being the fastest escalating markets in the region. The important steering forces for the market in developing economies are large patient pools, improvements in healthcare infrastructure, increasing private and public support in order to develop HLA technologies, and growing emphasis of life science organizations in the region.